Abbott laboratories (ABT)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10Dec'09Sep'09Jun'09Mar'09
Cash Flow From (Used in) Operating Activities:
Net earnings

3,579

3,687

3,292

2,895

2,622

2,368

886

926

476

477

2,103

1,171

1,503

1,400

1,369

2,278

2,447

4,423

4,560

4,519

4,201

2,284

1,969

2,396

2,407

2,576

3,040

4,017

5,264

5,963

6,527

4,888

5,106

4,728

4,550

5,138

4,486

4,626

4,724

5,313

5,310

5,745

0

0

0

Adjustments to reconcile net earnings to net cash from operating activities -
Depreciation

1,078

1,078

1,080

1,079

1,099

1,100

1,108

1,094

1,062

1,046

961

906

852

803

828

860

859

871

877

871

909

918

917

930

930

928

957

1,148

1,230

1,363

1,346

1,336

1,395

1,395

1,457

1,349

1,274

1,207

1,228

1,227

1,228

1,210

0

0

0

Amortization of intangible assets

2,011

1,936

1,941

2,001

2,080

2,178

2,250

2,207

2,037

1,975

1,536

1,175

928

550

572

583

589

601

624

602

612

630

662

730

766

791

923

1,055

1,228

1,419

1,496

1,585

1,646

1,649

1,647

1,593

1,533

1,416

1,233

1,097

959

878

0

0

0

Derecognition of a contingent liability associated with the conclusion of the TAP Pharmaceutical Products Inc. joint venture

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-797

0

0

0

Share-based compensation

526

519

515

504

491

477

464

456

447

406

385

359

329

310

306

301

296

292

287

283

275

246

248

253

255

262

296

326

361

433

421

413

404

383

377

381

389

387

389

379

353

366

0

0

0

Amortization of inventory step-up

-

-

-

-

-

32

99

117

547

907

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Impact of currency devaluation

-

-

-

-

-

-

-

-

-

-

-

-

-

480

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gains on sale of businesses

-

-

-

-

-

-

-

-

-

1,163

1,163

1,151

1,151

25

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Gain on sale of discontinued operations

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Trade receivables

209

275

267

388

307

190

318

288

290

207

230

83

143

177

136

196

85

171

173

244

367

195

308

98

21

113

631

798

106

-36

253

442

836

670

598

124

387

394

421

569

471

387

0

0

0

Inventories

744

593

794

718

629

514

240

-40

-240

-249

-93

76

165

98

196

196

224

257

307

366

335

297

115

63

112

154

193

269

378

417

642

559

345

130

-240

-215

-234

-139

-263

-485

-379

-230

0

0

0

Acquired in-process and collaborations research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

288

659

659

722

672

0

0

0

-

-

-

-

-

-

-

-

Other, net

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

-

0

0

0

Net Cash From Operating Activities

6,139

6,136

5,485

5,720

5,904

6,300

6,175

5,997

6,104

5,570

5,100

4,312

3,870

3,203

2,861

2,839

2,871

2,966

3,376

3,382

3,341

3,675

4,062

3,383

3,200

3,324

3,201

6,199

7,549

9,314

9,212

8,747

9,183

8,970

9,885

9,379

9,224

8,735

8,252

8,733

8,099

7,275

0

0

0

Cash Flow From (Used in) Investing Activities:
Acquisitions of property and equipment

1,663

1,638

1,671

1,624

1,454

1,394

1,272

1,181

1,138

1,135

1,109

1,158

1,150

1,121

1,050

1,149

1,118

1,110

1,149

1,015

1,057

1,077

1,093

1,093

1,126

1,145

1,227

1,481

1,615

1,795

1,683

1,604

1,552

1,491

1,508

1,261

1,161

1,015

969

1,092

1,082

1,089

0

0

0

Acquisitions of businesses and technologies, net of cash acquired

-

170

182

171

107

54

4,199

4,199

4,181

17,183

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

706

0

0

0

-

-

-

-

9,433

9,971

7,781

7,294

2,370

0

0

0

Proceeds from business dispositions

-

-

-

-

-

-

-

-

-

6,042

5,442

5,471

5,472

25

25

25

25

230

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from the sale of Mylan N.V. shares

-

-

-

-

-

-

-

-

-

2,704

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of investment securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

9,932

11,998

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Sales (purchases) of other investment securities, net

0

-

0

0

0

-

0

0

-139

-

-4,593

-4,481

-3,248

-3,709

-5,756

-5,368

-4,771

-4,112

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-5,649

2,112

4,030

1,836

-954

-4,885

-3,693

-751

-16

0

0

0

Deposit of restricted funds

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Other

-15

-27

-40

-48

-50

-102

-90

-81

-99

-35

-38

-41

-47

-42

-43

-52

-37

-52

-51

-71

-56

-70

0

0

0

-

-

-

-

-3

-8

-15

-19

-16

1

0

8

18

10

10

7

6

0

0

0

Net Cash (Used in) Investing Activities

-1,812

-1,815

-1,822

-1,713

-1,514

-1,356

-4,012

-3,995

-3,702

-9,618

-4,916

-5,164

-6,628

-248

-232

-875

837

406

-1,170

-798

188

-202

648

-1,224

-2,416

-3,929

-5,993

-3,428

-2,776

-5,560

-2,570

-1,446

-1,929

661

-3,544

-6,929

-6,830

-12,188

-8,185

-7,310

-9,751

-3,698

0

0

0

Cash Flow From (Used in) Financing Activities:
Net borrowings (repayments) of short-term debt and other

0

-

4

-126

-19

-26

412

535

427

-1,034

-2,509

-2,911

-2,639

-1,767

56

-48

-393

-1,281

-1,945

-1,047

-1,341

1,343

-169

-192

1,051

2,086

3,519

1,237

1,632

784

-389

-442

-962

-1,965

428

2,316

-582

-203

-483

-675

2,221

3,217

0

0

0

Proceeds from issuance of long-term debt and debt with maturities over 3 months

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,485

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

3,000

0

0

0

Repayments of long-term debt

2,942

3,441

4,677

5,674

6,954

12,433

14,421

13,423

12,124

8,650

2,509

2,509

2,510

12

32

34

54

57

0

0

0

-

-

-

-

-

-

-

-

11,071

1,057

1,059

2,565

3,012

3,681

3,679

2,173

1,673

1

1

501

2,483

0

0

0

Payment of contingent consideration

-

-

-

-

-

-

-

-

-

-

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of common shares

737

718

326

328

327

238

145

150

150

117

106

100

98

522

1,410

1,410

1,410

2,237

1,350

1,349

1,349

2,195

2,233

2,583

2,872

1,605

2,206

1,856

2,301

2,364

1,725

1,725

992

77

75

76

77

866

867

865

864

826

0

0

0

Proceeds from stock options exercised

260

298

318

345

261

271

319

334

358

350

317

304

290

248

257

231

245

314

402

416

415

429

505

479

496

395

459

945

1,231

1,850

2,221

1,745

1,480

969

373

394

315

328

458

419

417

508

0

0

0

Dividends paid

2,343

2,270

2,197

2,122

2,048

1,974

1,943

1,912

1,880

1,849

1,771

1,692

1,614

1,539

1,513

1,488

1,464

1,443

1,418

1,390

1,363

1,342

1,225

1,114

1,001

882

1,476

2,061

2,648

3,183

3,122

3,069

3,012

2,938

2,878

2,805

2,734

2,671

2,598

2,537

2,476

2,414

0

0

0

Net Cash (Used in) Financing Activities

-3,882

-4,289

-6,880

-3,896

-5,078

-10,391

-5,727

-8,584

-7,337

-5,281

8,335

7,975

8,180

11,147

-2,854

-2,923

-3,118

-2,236

-2,439

-1,895

-2,140

-2,742

-3,911

-4,199

-3,115

-6,696

-2,321

-4,353

-4,703

195

-3,994

-4,071

-5,573

-6,423

-4,831

-2,850

-1,251

-1,087

-491

-660

-1,202

1,002

0

0

0

Transfer of cash and cash equivalents to AbbVie Inc.

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5,901

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contingent consideration payment related to a business acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Effect of exchange rate changes on cash and cash equivalents

-90

-16

-61

-39

-147

-116

-79

-28

86

116

-7

-26

-50

-483

-407

-511

-482

-198

-248

-211

-223

-143

-68

38

18

-26

-1

102

-42

40

300

-252

-74

-43

-278

156

31

-620

-633

-645

-452

118

0

0

0

Net Decrease in Cash and Cash Equivalents

355

16

-3,278

72

-835

-5,563

-3,643

-6,610

-4,849

-9,213

8,512

7,097

5,372

13,619

-632

-1,470

108

938

-481

478

1,166

588

731

-2,002

-2,313

-7,327

-5,115

-1,480

26

3,989

2,948

2,976

1,606

3,165

1,231

-244

1,173

-5,160

-1,057

117

-3,307

4,697

0

0

0